SCHEMBL5727593

SCHEMBL5727593

O=C(c1cccc(Cl)c1)c1ccc2c(c1)[S+]([O-])CN2

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.40
FEN1 P39748 1/20 0.40
PARP1 P09874 1/20 0.40
HDAC8 Q9BY41 1/20 0.38
ALOX15 P16050 2/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
MAPK7 Q13164 1/20 0.36
MAPK14 Q16539 1/20 0.36
ALDH1A1 P00352 1/20 0.36
VNN1 O95497 1/20 0.36
KCNMA1 Q12791 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PKM P14618 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9685893 0.89 CNR2 (0.36)
SCHEMBL9483366 0.88 SRD5A2 (0.41) ERCC5FEN1ALOX15CA1CA2
SCHEMBL5727289 0.86 ATM (0.44) ALDH1A1L3MBTL1
SCHEMBL5727272 0.84 PARP1 (0.40) PARP1CA12CA1CA2CA7
SCHEMBL9483959 0.81 HTT (0.45) CA12CA1CA2CA7CA9
SCHEMBL9483334 0.76 ALDH1A1 (0.48) CA1CA2ALDH1A1
SCHEMBL5727378 0.76 MAPT (0.39) ALOX15ALDH1A1L3MBTL1PKM
SCHEMBL9484177 0.75 HPGD (0.45) ALDH1A1
SCHEMBL3445668 0.73 PARP1 (0.63) ERCC5FEN1PARP1ALOX15ALDH1A1
SCHEMBL3173817 0.72 PARP1 (0.68) ERCC5FEN1PARP1ALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1502590-B1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes SERVIER LAB (FR) 2006-12-20 EP disclosed
US-7071221-B2 Heterocyclic oxime compounds LES LABORATOIRES SERVIER (FR) 2006-07-04 US disclosed
US-20050026973-A1 New heterocyclic oxime compounds LES LABORATOIRES SERVIER (FR) 2005-02-03 US disclosed
EP-1502590-A1 Heterocyclic oxime derivatives, process for their preparation and use thereof in the treatment of type II diabetes Les Laboratoires Servier (FR) 2005-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026973-A1 New heterocyclic oxime compounds CBR3, CBR1, CYB5R3 ERCC5 2517/4885FEN1 2897/4885PARP1 1713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.